Clinical trial NCT05041842: Treatment With Tucatinib in Patients With an Isolated Brain Progression of a Metastatic Breast Cancer
Official title: Treatment With Tucatinib in Addition to Pertuzumab and Trastuzumab in Patients With HER2-positive Metastatic Breast Cancer After Local Therapy of Isolated Brain Progression
Study type: INTERVENTIONAL
Overall status: ACTIVE_NOT_RECRUITING
Phase: PHASE2
Conditions: Metastatic Breast Cancer With a Isolated Brain Progression
Lead sponsor: UNICANCER
Sponsor class: OTHER
Collaborators: name: Seagen Inc.
name: ARCAGY/ GINECO GROUP
First posted: 2021-09-13
Enrollment: 53
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Intervention model description: Patients treated with pertuzumab and trastuzumab for metastatic breast cancer who will develop an isolated brain relapse treated with local treatment will receive tucatinib in addition to pertuzumab and trastuzumab. Tucatinib will be taken orally 300 mg twice a day, pertuzumab (420 mg) and trastuzumab (6 mg/kg) will be taken every 3 weeks.
Primary purpose: TREATMENT

Brief summary: The overall survival of patients with metastatic breast cancer has steadily improved over the past decades, mainly due to advances in systemic treatment. Despite these advances, the development of brain metastases remains a serious and devastating complication that decreases quality of life and increases morbidity and mortality. The HER2CLIMB randomized study demonstrated that adding the investigational drug tucatinib to the standard treatment trastuzumab and capecitabine improved both progression-free survival and overall survival in people diagnosed with human epidermal growth factor 2 (HER2)-positive metastatic breast cancer, previously treated with trastuzumab, pertuzumab, and T-DM1. In patients with brain metastases, the 1-year progression-free survival was 25% in the tucatinib group and 0% in the placebo group.

These results suggest that tucatinib may be a new standard treatment for HER2-positive metastatic disease.

The aim of the non-randomized phase II study, InTTercePT, is to evaluate the effectiveness of adding tucatinib to trastuzumab and pertuzumab in the event of cerebral progression, after the end of local treatment.

Detailed description: The overall survival of patients with metastatic breast cancer has steadily improved over the past decades, mainly due to advances in systemic treatment. Despite these advances, the development of brain metastases remains a serious and devastating complication that decreases quality of life and increases morbidity and mortality. More than a third of patients with HER2-positive breast cancer develop brain metastases during the course of the disease. For patients with isolated brain progression, local treatment is recommended whenever possible (stereotaxic radiosurgery and / or surgery) as well as the continuation of systemic treatment previously initiated even if the evidence of a benefit is weak.

After local treatment these patients will have a higher risk of progression (cerebral and systemic). Therefore, the question of whether systemic treatment should be continued or changed remains an open question.

In a pooled analysis of two phase 1b studies, patients who continued systemic treatment with tucatinib (in combination with T-DM1 or with trastuzumab and capecitabine) after treatment directed to the central nervous system demonstrated a better prognosis than that of patients who stopped tucatinib.

The HER2CLIMB randomized study demonstrated that adding the investigational drug tucatinib to the standard treatment trastuzumab and capecitabine improved both progression-free survival and overall survival in people diagnosed with HER2-positive metastatic breast cancer, previously treated with trastuzumab, pertuzumab, and T-DM1. In patients with brain metastases, the 1-year progression-free survival was 25% in the tucatinib group and 0% in the placebo group.

These results suggest that tucatinib may be a new standard treatment for HER2-positive metastatic disease.

We anticipate that adding tucatinib to the trastuzumab / pertuzumab regimen will control brain metastases, prolong progression-free survival, and improve patient quality of life.

The aim of the non-randomized phase II study, InTTercePT, is to evaluate the effectiveness of adding tucatinib to trastuzumab and pertuzumab in the event of cerebral progression, after the end of local treatment.

Eligibility criteria: Inclusion Criteria:

1. Male or female, Age ≥18;
2. Eastern Cooperative Oncology Group Performance Status (ECOG PS) 0-1;
3. Histologically confirmed HER2 positive breast cancer, with HER2 positive defined by in situ hybridization (ISH), immunohistochemistry (IHC), or fluorescence in situ hybridization (FISH) methodology;
4. Documented isolated brain progression (defined as new or progressive brain metastases with stable or responding systemic disease) under pertuzumab and trastuzumab treatment (with or without taxane) for metastatic disease (There is no limit to the number and size of brain metastasis);
5. Complete local treatment of brain progression (Surgery and/or radiation therapy) should have been completed no more than 12 weeks before inclusion and there is no clinical indication for immediate re-treatment with local therapy in the opinion of the investigator;
6. Able to undergo MRI scanning of the brain;
7. Normal renal function: creatinine \<1.5 x upper limit of normal (ULN);
8. Adequate liver function: total bilirubin ≤1.5 ULN (unless documented Gilbert's syndrome); aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤2.5 ULN (≤5 ULN in the presence of liver metastases);
9. Normal hematological function: Absolute neutrophil count (ANC) ≥1.5 x 10⁹/L; platelets count ≥100 x 10⁹/L; and hemoglobin ≥9.0 g/dL;
10. Adequate cardiac functions, including:

    * 12 Lead electrocardiograms (ECG) with normal tracing or non-clinically significant changes that do not require medical intervention
    * QT/Corrected QT interval (QTcF) ≤470 msec for woman and ≤450 msec for men (mean of replicate values, correction per institutional standard) on the ECG at the screening visit and a normal kalemia
    * Left ventricular ejection fraction (LVEF) ≥50%
    * No history of Torsades de Pointes or other symptomatic QTc abnormality
11. Resolution of all acute toxic effects of prior anti-cancer therapy or surgical procedures to NCI CTCAE version 5.0 Grade 1 or to baseline (except alopecia or others toxicities not considered a safety risk for the patient at investigator's discretion);
12. Stable dose of steroids at the time of enrolment;
13. Women of childbearing potential must have a negative pregnancy test (blood or urine test) within 14 days prior to inclusion;
14. Woman of childbearing potential and male patients must agree to use adequate contraception for the duration of trial participation and up to 7 months after completing treatment/therapy (association of trastuzumab, pertuzumab +/- tucatinib). Hormonal contraceptives such as birth control pills, patches, implants, or injections are not allowed in patients who are hormone receptor positive;
15. Patient must have signed a written informed consent form prior to any trial specific procedures. When the patient is physically unable to give their written consent, a trusted person of their choice, independent from the investigator or the sponsor, can confirm in writing the patient's consent;
16. Patients affiliated to the social security system (or equivalent);
17. Patient must be willing and able to comply with the protocol for the duration of the trial including scheduled visits, treatment plan, laboratory tests, and examinations including follow-up.

Exclusion Criteria:

1. Radiologic extra-cranial progression under pertuzumab and trastuzumab treatment, at the time of enrolment. The systemic disease must be stable or responding at the time of enrolment;
2. Proven leptomeningeal disease;
3. Any progressive brain lesion between the brain local treatment completion and the enrolment;
4. Poorly controlled seizures (more than 1/week);
5. Clinically significant cardiopulmonary disease;
6. Used of a strong cytochrome P450 (CYP)2C8 inhibitor within 5 half-lives of the inhibitor, or use of a strong CYP3A4 or CYP2C8 inducer within 5 days prior to first dose of study treatment. Use of sensitive CYP3A substrates should be avoided one week before enrollment and during study treatment
7. Previous treatment with a tyrosine kinase inhibitor;
8. Carriers of Hepatitis B or Hepatitis C or have other known chronic liver disease;
9. Positive for human immunodeficiency virus (HIV);
10. Known prior severe hypersensitivity to tucatinib or compounds chemically or/and biologically similar or any component in its formulation;
11. History of any other cancer (except non-melanoma skin cancer or carcinoma in-situ of the cervix) unless the patient has been in remission and off all other cancer therapy for at least 3 years;
12. Pregnant women or women who are breast-feeding;
13. Inability to swallow tablets or significant gastrointestinal disease which would preclude the adequate oral absorption of medications;
14. Person deprived of their liberty or under protective custody or guardianship or unable to give informed consent;
15. Participation in another therapeutic trial within the 30 days prior to tucatinib treatment initiation.

Primary outcomes:
measure: Progression-Free Survival
timeFrame: 6 months
Secondary outcomes:
measure: Overall Survival
timeFrame: Throughout study completion, up to 18 months
measure: Brain Progression-Free Survival
timeFrame: Throughout study completion, up to 18 months
measure: Overall brain metastasis response
timeFrame: Throughout study completion, up to 18 months
measure: Incidence of treatment-emergent Adverse Events
timeFrame: Throughout study completion, up to 18 months
Other outcomes:
Locations:
city: Angers
country: France
facility: Institut de Cancérologie de l'Ouest - Site Paul Papin
city: Caen
country: France
facility: Centre Francois Baclesse
city: Dijon
country: France
facility: Centre Georges François Leclerc
city: Le Mans
country: France
facility: Clinique Victor Hugo
city: Lyon
country: France
facility: Centre Leon Berard
city: Lyon
country: France
facility: Hôpital privé Jean Mermoz
city: Montpellier
country: France
facility: CRLC Val d'Aurelle
city: Nice
country: France
facility: Centre Antoine Lacassagne
city: Plerin
country: France
facility: CARIO - Centre Armoricain Radiothérapie Imagerie Médicale et Oncologi
city: Pringy
country: France
facility: Centre Hospitalier Annecy Genevois
city: Reims
country: France
facility: Institut Jean Godinot
city: Rouen
country: France
facility: Centre Henri Becquerel
city: Toulouse
country: France
facility: Institut Claudius Regaud
city: Tours
country: France
facility: Centre Hospitalier Universitaire de Tours
city: Villejuif
country: France
facility: Gustave Roussy
Study officials:
affiliation: Centre Leon Berard
name: Thomas Bachelot, MD
role: PRINCIPAL_INVESTIGATOR
affiliation: Centre Armoricain d'Oncologie
name: Anne-Claire Hardy-Bessard, MD
role: PRINCIPAL_INVESTIGATOR
References: